On April 23, 2019, the National Institute of Mental Health (NIMH) Office of Autism Research Coordination (OARC) will host a special event to recognize National Autism Awareness Month.
Source: nimh

Researchers have developed a high-tech support system that can keep a large mammalian brain from rapidly decomposing in the hours after death, enabling study of certain molecular and cellular functions.
Source: nimh

In April 2019, the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) Unit, the Delaware Project, and the Association for Behavioral and Cognitive Therapies (ABCT) will conduct the third webinar in a series examining the science-to-service pipeline in psychology and psychiatry.
Source: nimh

Researchers have identified ketamine-induced brain-related changes that are responsible for maintaining the remission of behaviors related to depression in mice — findings that may help researchers develop interventions that promote lasting remission of depression in humans.
Source: nimh

The 10th Anniversary Conference: Global Mental Health Research without Borders, will showcase findings from cutting-edge science and identify opportunities for new groundbreaking research to address the grand challenges in global mental health.
Source: nimh

On April 11-13, 2019, approximately 1,500 scientists from many disciplines will attend the fifth annual Brain Research through Advancing Innovative Neurotechnologies (BRAIN)® Initiative Investigators Meeting in Washington, DC. This open meeting provides a forum for discussing scientific developments and potential new directions, and to identify areas for collaboration and research coordination.
Source: nimh

Vikram Harshad Patel, M.B.B.S., Ph.D., whose research has been funded by the National Institute of Mental Health (NIMH), will receive the John Dirks Canada Gairdner Award for Global Health. This honor recognizes the world’s top scientists and their outstanding achievements in global health research. Dr. Patel will receive the award on October 24, 2019, in Toronto, Canada.
Source: nimh

In this message, Dr. Gordon discusses the role of NIMH and others in the bench-to-bedside story of bexanolone, which has just been approved by the FDA as the first treatment specifically for postpartum depression.
Source: nimh

This webinar highlights three NIMH supported research studies that leverage mobile technology to address mental health challenges such as depression and substance use in lower middle-income countries. The purpose of the webinar is to introduce or enhance knowledge on how mobile health technologies establish research networks, build capacity and improve mental health outcomes in low to middle income countries.
Source: nimh

FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.
Source: nimh